SPRB (Spruce Biosciences Inc.) רווח למניה בארבעת הרבעונים האחרונים

Spruce Biosciences (SPRB) is implementing breakthrough methods for hormone correction at the genetic level, and the historical YoY EPS growth over the last 12 months on GURU.Markets yields 58.60, which expresses the metric's value today. High pricing power is driven by the uniqueness of tildacerfone amid inelastic demand. However, a cash deficit and failed tests are forcing the company to aggressively optimize expenses to maintain liquidity.

Spruce Biosciences invests in clinical trials for rare hormonal pathology therapies through partnerships with endocrinology centers. R&D expenses for such developments directly impact net income, which forms the basis for calculating earnings per share. This indicator measures the annual change in EPS over the last 12 months, eliminating the blind spots of quarterly reporting. Analyzing the annual EPS TTM delta allows for an assessment of the issuer's financial resilience to crises. The trend along this curve helps investors recognize the risk of overpaying for the asset in a timely manner.